AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Microsomal glutathione S-transferase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q99735

UPID:

MGST2_HUMAN

Alternative names:

Glutathione peroxidase MGST2; Leukotriene C4 synthase MGST2; Microsomal glutathione S-transferase II

Alternative UPACC:

Q99735; D6RBB5; Q7Z5B8

Background:

Microsomal glutathione S-transferase 2 (MGST2) plays a pivotal role in cellular defense mechanisms. It catalyzes various glutathione-dependent reactions, including the reduction of lipid hydroperoxides and the detoxification of xenobiotic electrophiles. MGST2 also facilitates the conjugation of leukotriene A4 to form leukotriene C4, a process crucial for inflammatory responses.

Therapeutic significance:

Understanding the role of Microsomal glutathione S-transferase 2 could open doors to potential therapeutic strategies. Its involvement in oxidative DNA damage repair and the biosynthesis of inflammatory mediators highlights its potential as a target in treating diseases related to oxidative stress and inflammation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.